Completion of ACTIV-2 Study
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N93021D00035-0-759302200002-1
Grant search
Key facts
Disease
COVID-19Start & end year
20222024Known Financial Commitments (USD)
$82,531,927Funder
National Institutes of Health (NIH)Principal Investigator
ANGEE GREERResearch Location
United States of AmericaLead Research Institution
PPD DEVELOPMENT LPResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Clinical trial (unspecified trial phase)Special Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support, NIAID serves as the sponsor for the COVID-19 clinical trial entitled "A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)" also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.